Alivus Life Sciences
Alivus Life Sciences Share Price Chart
Alivus Life Sciences last traded at ₹1,341.30 (2026-10-13). Over the past month the stock moved -3.8%, three months the stock moved +23.0%, year the stock moved +28.1%. Its closing range over 52 weeks is ₹880.15 – ₹1,449.00, with the latest close 7.4% below the high.
Closing prices up to 2026-10-13.
About Alivus Life Sciences
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
History Before 2019 API business was an integral part of Glenmark Pharma (GPL). It was separated from GPL into GLS through a Business Transfer Agreement in Jan 2019, and GLS was subsequently listed on NSE & BSE in FY22. [1]
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Alivus Life Sciences reported sales of ₹640.00 crore (+6.3%) and net profit of ₹160.00 crore (+31.1%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 640.00 | 212.00 | 33.00 | 160.00 | 13.04 |
| Mar 2026 | 689.00 | 215.00 | 31.00 | 163.00 | 13.25 |
| Dec 2025 | 673.00 | 231.00 | 34.00 | 150.00 | 12.25 |
| Sep 2025 | 588.00 | 179.00 | 30.00 | 130.00 | 10.60 |
| Jun 2025 | 602.00 | 172.00 | 29.00 | 122.00 | 9.91 |
| Mar 2025 | 650.00 | 198.00 | 31.00 | 142.00 | 11.58 |
| Dec 2024 | 642.00 | 190.00 | 30.00 | 137.00 | 11.18 |
| Sep 2024 | 507.00 | 134.00 | 27.00 | 95.00 | 7.78 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | -14.8% | +12.0% | +21.0% | +2.2% | +16.0% | +4.8% | +6.0% | +6.3% |
| Operating profit growth | -19.8% | +9.8% | +40.4% | +8.2% | +33.6% | +21.6% | +8.6% | +23.3% |
| Net profit growth | -20.2% | +15.1% | +44.9% | +9.9% | +36.8% | +9.5% | +14.8% | +31.1% |
| EPS growth | -19.7% | +15.4% | +44.9% | +8.9% | +36.2% | +9.6% | +14.4% | +31.6% |
| OPM % | 27.0% | 30.0% | 31.0% | 29.0% | 30.0% | 34.0% | 31.0% | 33.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Alivus Life Sciences reported sales of ₹2,552.00 crore (+6.9%) and net profit of ₹564.00 crore (+16.0%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 2,552 | 797.00 | 31.00 | 564.00 | 45.99 |
| Mar 2025 | 2,387 | 683.00 | 29.00 | 486.00 | 39.63 |
| Mar 2024 | 2,283 | 675.00 | 30.00 | 471.00 | 38.43 |
| Mar 2023 | 2,161 | 643.00 | 30.00 | 467.00 | 38.11 |
| Mar 2022 | 2,123 | 617.00 | 29.00 | 419.00 | 34.17 |
| Mar 2021 | 1,885 | 592.00 | 31.00 | 352.00 | 358.74 |
| Mar 2020 | 1,537 | 473.00 | 31.00 | 313.00 | 1,597.37 |
| Mar 2019 | 886.00 | 248.00 | 28.00 | 196.00 | 997.86 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | – | +73.5% | +22.6% | +12.6% | +1.8% | +5.6% | +4.6% | +6.9% |
| Operating profit growth | – | +90.7% | +25.2% | +4.2% | +4.2% | +5.0% | +1.2% | +16.7% |
| Net profit growth | – | +59.7% | +12.5% | +19.0% | +11.5% | +0.9% | +3.2% | +16.0% |
| EPS growth | – | +60.1% | -77.5% | -90.5% | +11.5% | +0.8% | +3.1% | +16.0% |
| OPM % | 28.0% | 31.0% | 31.0% | 29.0% | 30.0% | 30.0% | 29.0% | 31.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Alivus Life Sciences.
Get Free AI Stock Analysis FREE →Latest News
-
Alivus Life Sciences schedules investor meetings with Mirae Asset, Emkay - scanx.trade
-
Alivus Lifesciences Bull Case Target Achieved
-
Alivus Lifesciences Bull Case Target Achieved
-
Alivus Lifesciences Bull Case Target Achieved
-
Alivus Lifesciences Bull Case Target Achieved
-
Alivus Lifesciences Base Case Target Achieved
Frequently Asked Questions
What is the share price of Alivus Life Sciences today?
Alivus Life Sciences shares were last quoted at ₹1,341.30 (+1.1% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Alivus Life Sciences?
Alivus Life Sciences has a price-to-earnings (P/E) ratio of 27.79 and a price-to-book (P/B) ratio of 4.80. The industry P/E is 53.33.
What is the 52-week high and low of Alivus Life Sciences?
The 52-week high of Alivus Life Sciences is ₹1,495.30 and the 52-week low is ₹830.00.
What is the market cap of Alivus Life Sciences?
The market capitalisation of Alivus Life Sciences is about ₹16,760.76 crore.
How did Alivus Life Sciences perform in its latest quarterly results?
In the latest quarter (Jun 2026), Alivus Life Sciences reported sales of ₹640.00 crore (+6.3%) and net profit of ₹160.00 crore (+31.1%), compared with the same quarter last year.
Is Alivus Life Sciences a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Alivus Life Sciences has a 3-year ROE of 19.00%, 3-year profit growth of 8.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Alivus Life Sciences?
Promoters hold about 74.87% of Alivus Life Sciences.
Which sector does Alivus Life Sciences belong to?
Alivus Life Sciences belongs to the Pharmaceuticals & Drugs sector.